Jumpei Aida

Jumpei Aida

Auto-generated profile, based on publicly available information

Jumpei Aida

Takeda Pharmaceutical Company Limited, 26-1 Muraoka-Higashi 2-chrome, Fujisawa, Kanagawa 251-8555, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JAJumpei Aida
Jumpei Aida
MFMakoto Fushimi
Makoto Fushimi
TKTomokazu Kusumoto
Tomokazu Kusumoto
HSHideyuki Sugiyama
Hideyuki Sugiyama
NANaoto Arimura
Naoto Arimura
TKTatsuki Koike
Tatsuki Koike

30 July 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SIShuhei Ikeda
Shuhei Ikeda
HSHideyuki Sugiyama
Hideyuki Sugiyama
HTHidekazu Tokuhara
Hidekazu Tokuhara
MMMasataka Murakami
Masataka Murakami
MNMinoru Nakamura
Minoru Nakamura
MKMakoto Kamata
Makoto Kamata
The therapeutic potential of monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases has attracted attention worldwide. However, the availability of reversible-type inhibitor is still limited to clarify the pharmacological effect. Herein, we report the discovery of novel spiro chemical series as potent and reversible MAGL inhibitors with a different binding mode to MAGL using Arg57 and His121. Starting from hit compound 1 and its co-crystal structure with MAGL, structure-based drug discovery (SBDD) approach enabled us to generate various spiro scaffolds like 2a (azetidine-lactam), 2b (cyclobutane-lactam), and 2d (cyclobutane-carbamate) as novel bioisosteres of 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl moiety in 1 with higher lipophilic ligand efficiency (LLE). Optimization of the left hand side afforded 4f as a promising reversible MAGL inhibitor, which showed potent in vitro MAGL inhibitory activity (IC50 6.2 nM), good oral absorption, blood–brain barrier penetration, and significant pharmacodynamic changes (2-arachidonoylglycerol increase and arachidonic acid decrease) at 0.3–10 mg/kg, po. in mice.

9 September 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HFHideki Furukawa
Hideki Furukawa
YMYasufumi Miyamoto
Yasufumi Miyamoto
YHYasuhiro Hirata
Yasuhiro Hirata
KWKoji Watanabe
Koji Watanabe
YHYuko Hitomi
Yuko Hitomi
TMTsuyoshi Maekawa
Tsuyoshi Maekawa

12 October 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AOAtsutoshi Okabe
Atsutoshi Okabe
DCDaniel W. Carney
Daniel W. Carney
MTMichiko Tawada
Michiko Tawada
TAThamina Akther
Thamina Akther
JAJumpei Aida
Jumpei Aida
AOAtsuko Ochida
Atsuko Ochida
The COVID-19 pandemic has highlighted a clear need to ensure rapid and equitable global access to health interventions in preparation for future coronavirus-driven pandemics. Here, we report the discovery of highly potent noncovalent inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) with pan-coronavirus (pan-CoV) Mpro inhibition through computer-aided drug design. Virtual screening led to the identification of a noncovalent hit compound with a piperazine core. Structure-guided scaffold morphing provided a novel trisubstituted piperidine core. Free energy perturbation (FEP)-guided designs, with induced-fit of Met49/Met165 and Gln189, resulted in the identification of highly potent compound 30, which exhibits pan-CoV Mpro inhibition and cellular antiviral efficacy against the SARS-CoV-2 omicron variant. The optimized lead compound 30 was characterized by in vitro ADME/Tox assays and in vivo mouse pharmacokinetics. These findings suggest that compound 30 could be an addition to the repertoire of tools used to support future pandemic preparedness.

1 June 2021 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SKStephanie Kabeche
Stephanie Kabeche
JAJumpei Aida
Jumpei Aida
TAThamina Akther
Thamina Akther
TITakashi Ichikawa
Takashi Ichikawa
AOAtsuko Ochida
Atsuko Ochida
EYEllen Yeh
Ellen Yeh

23 August 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SMSatoru Matsuda
Satoru Matsuda
YHYasushi Hattori
Yasushi Hattori
KMKouta Matsumiya
Kouta Matsumiya
PMPaul McQuade
Paul McQuade
TYTohru Yamashita
Tohru Yamashita
HKHaruhide Kimura
Haruhide Kimura
Histone methylation is associated with the pathophysiology of neurodevelopmental disorders. Lysine-specific demethylase 1 (LSD1) catalyzes histone demethylation in a flavin adenine dinucleotide (FAD)-dependent manner. Thus, inhibiting LSD1 enzyme activity could offer a novel way to treat neurodevelopmental disorders. Assessing LSD1 target engagement using positron-emission tomography (PET) imaging could aid in developing therapeutic LSD1 inhibitors. In this study, PET probes based on 4-(2-aminocyclopropyl)benzamide derivatives that bind irreversibly to FAD found in LSD1 were examined. By optimizing the profiles of brain penetrance and brain-penetrant metabolites, T-914 (1g) was identified as a suitable PET tracer candidate. PET studies in nonhuman primates demonstrated that [18F]1g had heterogeneous brain uptake, which corresponded to known LSD1 expression levels. Moreover, brain uptake of [18F]1g was reduced by coadministration of unlabeled 1g, demonstrating blockable binding. These data suggest that [18F]1g warrants further investigation as a potential PET tracer candidate for assessing target engagement of LSD1.